- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02805023
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) (EnEPC-CLI)
Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)
Study Overview
Status
Intervention / Treatment
Detailed Description
BGC101 is designed to treat peripheral vascular disease in patients suffering from Critical Leg Ischemia (CLI) also referred to as chronic limb threatening ischemia (CLTI).
This part of the study is designed as a placebo double-blind randomized controlled trial (CRT) assessing the safety and efficacy of BGC101 in 45 eligible subjects in 2 Arms: Arm A: BGC101 treatment and Arm B: Placebo treatment. The Arm A:Arm B ratio is 2:1 A single dose treatment of the personalized cells by intramuscular injections into the affected leg takes less than 10 minutes.
Cells from a standard blood draw (with no pre-treatment, bone marrow aspiration, mobilization or apheresis) are transformed, within a day, into the investigational medicinal product BGC101.
BGC101, intended for autologous use, is a 'ready-to-use' cell suspension in prefilled syringes.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Mark Belokopytov, PHD
- Email: mark.belokopytov@biogencell.net
Study Contact Backup
- Name: Tilly Bernat, BSc
- Email: tbernat@laniado.org.il
Study Locations
-
-
-
Haifa, Israel, 31096
- Recruiting
- Rambam Health Care Campus
-
Contact:
- Ortal Bar-On
- Email: o_bar_on@rambam.health.gov.il
-
Principal Investigator:
- Tony Karram, MD
-
Netanya, Israel, 42150
- Recruiting
- Laniado Hospital
-
Contact:
- Mark Belokopytov, PHD
- Email: mark.belokopytov@biogencell.net
-
Contact:
- Tilly Bernat, BSc
- Phone Number: +972-8609118
- Email: tbernat@laniado.org.il
-
Principal Investigator:
- Shlomo Baytner, MD
-
-
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of San Francisco
-
Principal Investigator:
- Michael Conte, MD
-
Contact:
- Michael Conte, MD
- Email: michael.conte2@ucsf.edu
-
Contact:
- Donna Liu
- Email: donna.liu@ucsf.edu
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8039
- Recruiting
- Yale University School Of Medicine
-
Contact:
- Caelan Watts
- Email: caelan.watts@yale.edu
-
Principal Investigator:
- Edouard Aboian, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Hospital
-
Contact:
- Cheryl Lyn Errichetti
- Email: cerrich1@jhu.edu
-
Principal Investigator:
- Caitlin Hicks, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Have the time and ability to complete the study and comply with instructions.
- Capable of understanding of the purpose of the study and the contents of the informed consent form.
- Aged at least 18 years.
- Non-pregnant and non-lactating female patients.
- Have the clinical indications diagnostic of CLI based on Rutherford category 4-5
Have at least one of the hemodynamic indicators of severe peripheral arterial occlusive disease (WIfI ischemia grade 2):
- Toe pressure < 40 mmHg
- Ankle pressure < 70 mmHg
- TcPO2 < 40mmHg
Meeting one of the following conditions:
- Poor candidate for standard revascularization treatment for peripheral arterial disease due to unfavorable anatomy or high surgical/intervention risk based on the patient's underlying comorbidities.
After undergoing clinically ineffective revascularization. Six weeks or more after undergoing a prior index limb revascularization the patient demonstrates:
- No improvement in clinical signs and symptoms of CLI as evidenced by lack of improvement in rest pain (when not under increased pain relief) and/or inadequate wound healing or progression of tissue loss despite adequate standard treatment.
- Ongoing ischemia as defined above in the criterion 6.
- The patient is no longer amenable to further interventional or surgical revascularization (see inclusion criterion 7).
Exclusion criteria:
- Severe and uncorrected aorto-iliac and/or common femoral artery disease, i.e. absence of femoral pulse or monophasic common femoral artery doppler waveform.
- Concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the feasibility of the study medication.
- Treatment with any investigational product within the last 6 months or enrollment in any active study involving the use of investigational devices or drugs.
- Presence of any other condition or circumstance that, in the judgment of the investigator, might negatively impact the outcomes of the treatment under investigation.
- Prognosis of a major amputation (below or above the knee), within 4 weeks after screening.
- Severe wound (WIfI wound grade 2 or 3).
- Significant ongoing infection (WIfI infection grade 2 or 3).
- Relative or absolute contraindications for intramuscular injections at the intended treatment site, in cases such as severe skin lesions, severe edema or morbid obesity, based on clinician opinion.
- Blood transfusions during the preceding 4 weeks (to exclude the potential of non-autologous cells in the harvested blood).
- Heart failure (New York Heart Association [NYHA] 3-4).
- Patient suffering from active vasculitis.
- Hemoglobin (Hb) less than 9 g/dL.
- Patient with HbA1C > 8.5%
- Myocardial infarction, brain infarction, uncontrolled myocardial ischemia or persistent severe heart failure (ejection fraction [EF] < 25%) during the preceding 3 months.
- Significant valvular disease or valve replacement (based on medical record).
- Renal failure (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m², chronic kidney damage stage 4-5).
- Liver failure, Model for End-stage Liver Disease (MELD) scores 15 and higher.
- Liver function tests more than three times normal upper limit (normal limits being defined in each local laboratory) (glutamic-oxaloacetic transaminase [GOT], glutamic-pyruvic transaminase [GPT], alkaline phosphatase [AlkP], gamma-glutamyl transferase [GGT], lactate dehydrogenase [LDH]).
- Abnormal coagulation tests when not under warfarin (normalized prothrombin time [PT INR] >2).
- Pregnant or lactating women at entry of study.
- People who are unwilling to agree to use acceptable methods of contraception during the study.
- Malignancy within the preceding 3 years, except basal cell carcinoma.
- Concurrent acute infectious disease with septicemia
- Chronic infectious disease (human immunodeficiency virus-1 [HIV-1], human immunodeficiency virus-2 [HIV-2], hepatitis B virus [HBV], hepatitis C virus [HCV]).
- Immunodeficiency syndrome.
- Raynaud's syndrome
- Systemic treatment with cytotoxic and/or immunosuppressive treatment.
- Inability to communicate (that may interfere with the clinical evaluation of the patient).
- Patient unlikely to be available for follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Intramuscular injection of control medium only
|
Intramuscular injections - single treatment session
|
Experimental: BGC101
Intramuscular injection of BGC101 (autologous EnEPC preparation)
|
Intramuscular injections - single treatment session
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (Incidence of adverse events)
Time Frame: 12 Months
|
|
12 Months
|
Efficacy (Improvement of indication signs)
Time Frame: 12 Months
|
|
12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shlomo J Baytner, MD, Director of Vascular Surgery, Laniado Hospital, IL
- Principal Investigator: Michael Conte, MD, University of California, San Francisco - Division Vascular and Endovascular surgery
- Principal Investigator: Edouard Aboian, MD, Yale University School of Medicine- Division of Vascular Surgery, Department of Surgery
- Principal Investigator: Caitlin Hicks, MD, Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins Hospital
- Principal Investigator: Tony Karram, MD, Director Department of Vascular Surgery & Transplantation Rambam Health Care Campus - IL
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BioGenCell Ltd
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Control medium
-
Centre for Endocrinology and Reproductive Medicine...Completed
-
Clinical Nutrition Research Center, Illinois Institute...Barilla America, Inc.CompletedHealthy | AppetiteUnited States
-
Centre for Endocrinology and Reproductive Medicine...UnknownInfertility | Embryo Development | IVFItaly
-
University of OxfordOxford Fertility Limited, United KingdomUnknown
-
Mỹ Đức HospitalCompleted
-
The University of Hong KongKwong Wah HospitalCompletedIn Vitro Fertilization | SubfertilityHong Kong
-
Reproductive & Genetic Hospital of CITIC-XiangyaCompleted
-
TrichoScience Innovations, Inc.PRA Health Sciences; Pharmalog Institut für klinische Forschung GmbH (PHARMALOG... and other collaboratorsCompletedAndrogenetic AlopeciaGeorgia
-
King's College LondonUK Research and InnovationNot yet recruiting
-
Purdue UniversityAlliance for Potato Research and EducationCompletedBlood Pressure | Potassium BioavailabilityUnited States